PTH and secondary hyperparathyroidism: By contrast, the proportion of patients within the recommended ranges for phosphorus and parathyroid hormone was higher in 2023 (68% and 76%, respectively), denoting the greater expertise of nephrologists in treating bone disease and secondary hyperparathyroidism.